PLEK2 and esophageal squamous cell carcinoma: According to the results of functional studies, we detected the role of PLEK2 in enabling ESCC cells to be resistant to cisplatin, which would also provide the possibility that PLEK2 can become a marker that predicts the outcome, including chemoresistance and recurrence, of an ESCC patient who receives cisplatin therapy.